Thursday, July 26, 2012

DEA launches raid on sellers of designer drugs

DEA launches raid on sellers of designer drugs: The Drug Enforcement Administration is leading a national crackdown against manufacturers, distributors and vendors of synthetic designer drugs.

App gives autistic children a voice

App gives autistic children a voice:
An app is giving a voice to children with autism. For more CNN videos, check out our YouTube channel at Or visit our site at
More in

Alzheimer’s: tale of two proteins

Alzheimer’s: tale of two proteins: It now becomes clear that the best chance of preventing the disease lies in blocking the formation of both bap and tau, writes Clive Cookson

High quality global journalism requires investment. Please share this article with others using the link below, do not cut & paste the article. See our Ts&Cs and Copyright Policy for more detail. Email to buy additional rights.

July 6, 2012 9:11 pm

Alzheimer’s: a tale of two proteins

The best chance of preventing the disease lies in blocking the formation of both bap and tau
Human brain©Corbis
Drugs are being developed that target two proteins that build up in the brain of Alzheimer’s sufferers
The slow but inexorable spread of Alzheimer’s disease through millions of ageing brains is one of the 21st century’s great public health challenges – and research organisations are stepping up efforts to find better treatments than today’s drugs, which offer little more than short-term relief.
The fundamental problem is that scientists still understand little about the underlying processes that destroy the Alzheimer’s brain. Although researchers have known for decades that insoluble proteins build up and poison patients’ brains, they have long wrangled over the relative importance of the two main culprits: plaques of beta-amyloid protein (also known as bap or abeta) and tangles of tau. The dispute between “baptists” and “tauists” is a classic in the annals of academic argument.


IN FT Magazine

Now peace is breaking out, as it becomes clear that the two proteins are essential elements in Alzheimer’s development, and that in the long run, the best chance of preventing the disease or stopping its progress lies in blocking the formation of both bap and tau.
It is unlikely a single drug will successfully block both proteins but biotech companies and academic groups are developing new-wave drugs that target bap and tau individually. In future, these could be combined to make a dual-targeting Alzheimer’s treatment.
At the recent Bio conference in Boston a leading proponent of this approach – AC Immune, a Swiss biotech company – announced a new $418m research and development alliance with its commercial partner Genentech, the biotech arm of Switzerland’s Roche.

Down to Earth

The world’s oldest impact crater, a shallow bowl 100km across and formed when a comet or asteroid hit Earth three billion years ago, has been detected in Greenland.
The latest agreement adds a new anti-tau antibody to the companies’ existing $300m programme to produce an anti-abeta antibody, already in clinical trials under the name crenezumab.
“It seems that abeta appears in the brain earlier than tau in the development of Alzheimer’s – well before symptoms appear – but both are linked to later stages of the disease and a cure will need to address both,” says Andrea Pfeifer, AC Immune chief executive.
Crenezumab is about five years ahead of the anti-tau programme. The US National Institutes of Health selected crenezumab for the world’s first attempt to stave off Alzheimer’s in people at high risk of developing the disease. The 300 participants in the $100m NIH trial come from an extended family in Colombia whose members share a rare genetic mutation that typically triggers Alzheimer’s around the age of 45. The trial will show whether or not suppression of abeta plaques in the brain can delay the onset of memory loss and then dementia.
A significant delaying effect from crenezumab could make it an important drug – and a future partner for one of the anti-tau drugs at earlier stages of development.
Stem cell treatment gives sight to sore eyes
Although embryonic stem cells remain a hot political issue on both sides of the Atlantic, only one small biotechnology company is actively testing them in patients.
Last November, Geron stopped the world’s first clinical trial of embryonic stem cells – to repair nerve damage following spinal cord injury – for financial reasons. That left the embryonic field to Advanced Cell Technology (ACT), one of whose products aims to treat various forms of blindness.
Speaking to the FT at the recent Bio conference in Boston, Gary Rabin, ACT chief executive, and Bob Lanza, chief scientist, said the seven patients treated so far – for two progressive eye diseases, Stargardt’s disease and age-related macular degeneration (AMD) – were all doing well.
“Though the primary aim of these ‘phase one’ trials is to assess safety, we are seeing significant improvements in all seven patients,” says Lanza. “There is a real biological signal that the treatments are working.”
The treatment involves injecting retinal cells, grown from embryonic stem cells, into the eyes of people whose own cells have been destroyed by disease. As the new cells grow in the retina, the patient’s sight improves. It is unlikely anyone with advanced disease who is almost blind will have good eyesight restored; but the treatment could arrest the deterioration and preserve good sight for people still in early stages of Stargardt’s or AMD.
ACT’s schedule calls for a total of 36 patients to have been treated by early next year. These will include 12 Stargardt’s patients in the UK. In the US, another 12 Stargardt’s patients and 12 AMD patients will be treated.
The company says one advantage of its embryonic stem cells is that they are all derived from a single cell isolated “non-destructively” in 2005 from an embryo at an early development stage. Other embryonic stem cell lines used for research came from slightly older embryos, which would have been destroyed in the process.
A father with his baby©Dreamstime
Children of older fathers could age more slowly
Slow down ageing: get an old dad
Delaying paternity has had a bad press over the years, as more harmful mutations are likely to be transmitted to offspring by older fathers. But now there is some good news: if you avoid one of these disease-causing mutations, you are likely to age more slowly if you have an older father or grandfather.
A study of almost 2,000 people and their parents in the Philippines carried out by scientists from Northwestern University, Illinois, found that children of older fathers inherit longer telomeres. These are the protective DNA caps at the end of chromosomes. Longer telomeres are linked with slower ageing.
The association of paternal age with offspring telomere length is cumulative across multiple generations, so that someone with an older father and grandfather benefits more than someone with an older father and younger grandfather. The results are published in Proceedings of the National Academy of Sciences.
Christopher Kuzawa of Northwestern says evolutionary biology can explain the findings: “If our recent ancestors waited until later in adulthood before they reproduced, perhaps for cultural reasons, it would make sense for our bodies to prepare for something similar by investing the extra resources necessary to maintain healthy functioning at more advanced ages.”
However, the authors said men should not take their study as a recommendation to delay reproduction.
Give it a shot: the nicotine vaccine
A genetic vaccine against nicotine, which could help people stop smoking, has been tested successfully in laboratory mice.
Researchers at Weill Cornell Medical College in New York showed that a single shot of the novel vaccine protected mice against nicotine addiction for their lifetime. The study appears in the journal Science Translational Medicine.
The vaccine contains the genetic sequence of an antibody against nicotine inserted into a harmless virus, together with instructions that direct it to infect liver cells. The liver then acts as a bio-factory, making a steady stream of antibodies that consume nicotine when it enters the bloodstream, preventing most of the chemical from reaching the brain.
“As far as we can see, the best way to treat chronic nicotine addiction from smoking is to have these Pacman-like antibodies on patrol, clearing the blood as needed before nicotine can have any biological effect,” says lead author Ronald Crystal. “Our vaccine allows the body to make its own monoclonal antibodies against nicotine.” Previous vaccines failed because they delivered the antibodies directly and lasted only a few weeks.
“The use of gene therapy to treat ... a non-genetic psychological problem is a concept that would have been unthinkable 10 years ago,” says Robert MacLaren, a stem cell expert at the University of Oxford. “Whilst there may be easier ways of quitting smoking, it could be an exciting concept for other types of drug addiction.”
Copyright The Financial Times Limited 2012. You may share using our article tools.
Please don't cut articles from and redistribute by email or post to the web.

Colorado Shooting Suspect's Notebook Described Attack

  • James Holmes
  • James Holmes (Batman Shootings, Aurora, Colo.) - NYTimes Topic
  • James Holmes - YouTube

  • _______________________________________


    July 26, 2012

    Colorado Shooting Suspect's Notebook Described Attack

    by VOA News

    Law enforcement officials say the suspect in Friday's mass shooting at a Colorado movie theater sent a package to a university psychiatrist containing a notebook describing an attack.

    The package, which reportedly included stick figure drawings of a gunman shooting people, was sent before the shootings. The exact date is unknown.

    The University of Colorado Denver said the postal service delivered a suspicious package Monday, which was turned over to authorities within hours.

    Holmes was a Ph.D. student in neuroscience at the university before dropping out of the program last month.

    Prosecutors expect to formally charge Holmes on July 30, and he could face the death penalty if convicted.

    The July 20 shooting killed 12 people and wounded 58 others.

    Meanwhile, the first funeral was held Wednesday in the wake of the shooting. Gordon Cowden, who was 51, was the oldest of the victims.

    The Daily Star

    Batman shooter sent warning package to psychiatrist: report
    The Daily Star
    AURORA, Colorado: Alleged Colorado shooter James Holmes reportedly sent a warning package to a psychiatrist at his former university with a notebook and drawings of his plans to massacre people. Holmes, 24, is accused of shooting 12 people dead and ...
    Denver shooting suspect James Holmes may have shown plan to psychiatristThe Independent
    Experts didn't see trouble brewing with alleged Colorado shooterThe Daily Advertiser
    James Holmes spent year with neuroscientists before
    Newser -The Asian Age -Huffington Post
    all 241 news articles »